Cerus Corporation (CERS) reported quarterly earnings results on Tuesday, May-3-2016. The company reported $-0.17 EPS for the quarter. Analysts had a consensus estimate of $-0.17. The company posted revenue of $7.60 million in the period, compared to analysts expectations of $8.11 million. The company’s revenue was down -1.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.17 EPS.
Cerus Corporation closed down -0.02 points or -0.32% at $6.24 with 9,83,486 shares getting traded on Monday. Post opening the session at $6.26, the shares hit an intraday low of $6.11 and an intraday high of $6.29 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Mar 15, 2016, Chrystal Menard (Chief Legal Officer) sold 8,541 shares at $5.62 per share price. According to the SEC, on Sep 2, 2015, Laurence M Corash (Chief Scientific Officer) purchased 19,500 shares at $4.95 per share price.
Cerus Corporation is a biomedical products company engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens such as viruses including HIV West Nile SARS hepatitis B and C; bacteria and parasites as well as potentially harmful white blood cells while preserving the therapeutic properties of platelet plasma and red blood cell transfusion products. The Company has commercial rights for its INTERCEPT Blood System for three blood components: platelets plasma and red blood cells. The INTERCEPT Blood System for platelets or platelet system and the INTERCEPT Blood System for plasma or plasma system are being marketed and sold in a number of countries including the United States certain countries in Europe The Commonwealth of Independent States (CIS) and the Middle East. The INTERCEPT Blood System for red blood cells is in development-stage.